Abstract
siRNA has become an indispensable tool for functional characterization of genes. It has also demonstrated tremendous potential as a new generation of drug candidates. Although the technology works very well to a great panel of cells in vitro, it is still a challenge to translate the success into in vivo target validation easiness and, even more difficult, into therapeutic applications. With a number of chemically modified compounds under initial clinical trial from several commercial entities, the interests in chemical modification of siRNA have become heightened. In this review we have tried to touch on most of the chemical modifications of RNA that have been tested in the siRNA landscape, but maintained a focus on the backbone modifications, and 2-modifications on the ribose ring. It is anticipated that more modifications and more systematic comparisons between different modifications will be performed to draw more educated conclusions over some of the modifications.
Keywords: terminal modifications, RNA sugar ring, lactosylated-PEG-siRNA conjugates, oligonucleotides, Backbone modifications
Current Topics in Medicinal Chemistry
Title: RNA Interference with Chemically Modified siRNA
Volume: 6 Issue: 9
Author(s): Hong-Yan Zhang, Quan Du, Claes Wahlestedt and Zicai Liang
Affiliation:
Keywords: terminal modifications, RNA sugar ring, lactosylated-PEG-siRNA conjugates, oligonucleotides, Backbone modifications
Abstract: siRNA has become an indispensable tool for functional characterization of genes. It has also demonstrated tremendous potential as a new generation of drug candidates. Although the technology works very well to a great panel of cells in vitro, it is still a challenge to translate the success into in vivo target validation easiness and, even more difficult, into therapeutic applications. With a number of chemically modified compounds under initial clinical trial from several commercial entities, the interests in chemical modification of siRNA have become heightened. In this review we have tried to touch on most of the chemical modifications of RNA that have been tested in the siRNA landscape, but maintained a focus on the backbone modifications, and 2-modifications on the ribose ring. It is anticipated that more modifications and more systematic comparisons between different modifications will be performed to draw more educated conclusions over some of the modifications.
Export Options
About this article
Cite this article as:
Zhang Hong-Yan, Du Quan, Wahlestedt Claes and Liang Zicai, RNA Interference with Chemically Modified siRNA, Current Topics in Medicinal Chemistry 2006; 6 (9) . https://dx.doi.org/10.2174/156802606777303676
DOI https://dx.doi.org/10.2174/156802606777303676 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of IL-12 in Cancer
Current Cancer Drug Targets Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Radio-Susceptibility of Nasopharyngeal Carcinoma: Focus on Epstein- Barr Virus, MicroRNAs, Long Non-Coding RNAs and Circular RNAs
Current Molecular Pharmacology Nanomedicine: Enhancement of Chemotherapeutical Efficacy of Docetaxel by Using a Biodegradable Nanoparticle Formulation
Current Pharmaceutical Design Radioiodination of Pimonidazole as a Novel Theranostic Hypoxia Probe
Current Radiopharmaceuticals Harnessing Telomerase in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry The Canonical Wnt Signaling Pathway in Autism
CNS & Neurological Disorders - Drug Targets Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry
Current Metabolomics Molecular Chaperone Hsp90 as a Target for Oxidant-Based Anticancer Therapies
Current Medicinal Chemistry Role of HBV Replication in Host Cell Metabolism: A Proteomics Analysis
Current Proteomics 6-Membered Pyrrololactams: An Overview of Current Synthetic Approaches to their Preparation
Current Organic Chemistry Biomaterial Scaffolds for Mesenchymal Stem Cell Based Therapy Aimed at Tissue Engineering Application for Osteoarthritis
Recent Patents on Nanomedicine Effects of Carotenoids on Health: Are All the Same? Results from Clinical Trials
Current Pharmaceutical Design The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Preclinical Models to Study Breast Cancer
Clinical Cancer Drugs